The Metabolic Syndrome as Predictor of Type 2 Diabetes: The San Antonio Heart Study

Diabetes Care

Volumn 26, Issue 11, 2003, Pages 3153-3159

  Lorenzo, Carlos ^a   Okoloise, Mayor ^b   Williams, Ken ^b   Stern, Michael P ^b   Haffner, Steven M ^b  

^a Univ of Texas Hlth Science Center ^*  (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREDICTION; RISK FACTOR;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INCIDENCE; INSULIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 0242300702     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.11.3153     Document Type: Article

References (28)

1. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689, 2001
2. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716, 2002
3. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
4. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Geneva, World Health Org., 1999
5. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
6. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
7. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
8. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trail Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2097, 2002
9. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796-2803, 2002
10. Haffner SM, Hazuda HP, Mitchell BD, Patterson JK, Stern MP: Increased incidence of type II diabetes mellitus in Mexican Americans. Diabetes Care 14:102-108, 1991
11. Haffner SM, Miettinen H, Gaskill SP, Stern MP: Metabolic precursors of hypertension: the San Antonio Heart Study. Arch Intern Med 156:1994-2001, 1996
12. Haffner SM, Stern MP, Hazuda HP, Pugh JA, Patterson JK: Hyperinsulinemia in a population at high risk for non-insulin dependent diabetes mellitus. N Engl J Med 315:220-224, 1986
13. Balkau B, Charles MA: Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442-443, 1999
14. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA: Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 156:1070-1077, 2002
15. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837-845, 1988
16. American Diabetes Association: The prevention or delay of type 2 diabetes (Position Statement) Diabetes Care 25:742-749, 2002
17. US Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: recommendations and rationale. Ann Intern Med 138:212-214, 2003
18. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289:76-79, 2003
19. Centers for Disease Control and Prevention: National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2000. Atlanta, GA, U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention, 2002
20. Harris MI, Klein R, Welborn TA, Knuiman MW: Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15:815-81.9, 1992
21. The DECODE Study Group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397-405, 2001
22. Shaw JE, Zimmet PZ, de Courten M, Dowse GK, Chitson P, Gareeboo H, Hemraj F, Fareed D, Tuomilehto J, Alberti KG: Impaired fasting glucose or impaired glucose tolerance: what best predicts future diabetes in Mauritius? Diabetes Care 22:399-402, 1999
23. Stern MP, Williams K, Haffner SM: Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136:575-581, 2002
24. von Eckardstein A, Schulie H, Assmann G: Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular Munster. J Clin Eridocrinol Metab 85:3101-3108, 2000
25. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodriguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289:2363-2369, 2003
26. Davis M: New diagnostic criteria for diabetes: are they doing what they should? Lancet 354:610-611, 1999
27. Everson SA, Goldberg DE, Helmrich SP, Lakka TA, Lynch JW, Kaplan GA, Salonen JT: Weight gain and the risk of developing insulin resistance syndrome. Diabetes Care 21:1637-1643, 1998
28. Gregg EW, Gerzoff RB, Thompson TJ, Williamson DF: Intentional weight loss and death in overweight and obese U.S. adults 35 years of age and older. Ann Intern Med 138:383-389, 2003